Data / Form D filings / Avotres Inc.
Avotres Inc.: Form D filings
Avotres Inc., a biotechnology company in Hanover, NJ, filed 2 Form D notices with the SEC between 2021 and 2023. The latest, on May 4, 2023, reports $4 million sold of a $4.5 million offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 140 EAST HANOVER AVE., STE. 140, Hanover, NJ, 07927
- Phone
- (908) 591-9796
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1841331
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 4, 2023 | New notice | $4,500,000 | $4,000,000 | $500,000 | 3 | May 2, 2023 | sec.gov |
| Feb 24, 2021 | New notice | $8,000,000 | $4,000,000 | $4,000,000 | 3 | Dec 29, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Bruce Cooper | Director | |
| Dan Zhao | Director | |
| Jihong Chen | Director | |
| Xi Qin | Director | |
| Hong Jiang | Director | |
| Alex Li | Director | |
| John Houghton | Executive Officer | |
| Biao He | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of May 1, 2023 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Avotres Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.